ALZN
Alzamend Neuro, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.66
−2.35%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-1196.4%
Return on equity
-421.9%
Return on assets
-1195.7%
Return on invested capital
0.00x
Asset turnover
-$8.1M
Cash from operations
$0.15
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Apr 1, 2026